| pubmed-article:1317344 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1317344 | lifeskim:mentions | umls-concept:C0166049 | lld:lifeskim |
| pubmed-article:1317344 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1317344 | lifeskim:mentions | umls-concept:C2754997 | lld:lifeskim |
| pubmed-article:1317344 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:1317344 | lifeskim:mentions | umls-concept:C0237881 | lld:lifeskim |
| pubmed-article:1317344 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:1317344 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1317344 | pubmed:dateCreated | 1992-6-26 | lld:pubmed |
| pubmed-article:1317344 | pubmed:abstractText | We assessed the correlation between the positivity for serum IgM antibody to hepatitis C virus and the activity of liver disease in patients with chronic hepatitis C virus infection. Serum samples were taken from 10 antibody to hepatitis C virus-positive asymptomatic patients with normal serum ALT levels, from 14 untreated patients with clinically and histologically proven chronic hepatitis C and from 26 patients with clinically and histologically proven chronic hepatitis C assigned to receive recombinant interferon alpha-2a (6 million IU three times a week for 6 mo). Each serum specimen was tested for IgM antibody to hepatitis C virus-associated C100-3 antigen by enzyme-linked immunosorbent assay. Patients were observed for at least 12 mo. All 10 patients with normal ALT values tested negative for IgM antibody to hepatitis C virus. In contrast, 33 of 40 (82%) patients with chronic hepatitis C had IgM antibody to hepatitis C virus, and a positive correlation was seen between the ALT level and the level of IgM antibody to hepatitis C virus (r = 0.803, p less than 0.001). During interferon treatment, ALT levels declined into the normal range in 18 of 26 treated patients (69%) and remained normal after stopping treatment in 8 patients (31%). In untreated patients, in treated patients who did not respond to interferon treatment and in responder patients who relapsed, no significant changes in IgM antibody to hepatitis C virus levels were seen during the study period. In contrast, IgM antibody to hepatitis C virus became undetectable by the end of interferon treatment in seven of eight patients with a sustained response.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:1317344 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1317344 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1317344 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1317344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1317344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1317344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1317344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1317344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1317344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1317344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1317344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1317344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1317344 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1317344 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:1317344 | pubmed:issn | 0270-9139 | lld:pubmed |
| pubmed-article:1317344 | pubmed:author | pubmed-author:BarbaraLL | lld:pubmed |
| pubmed-article:1317344 | pubmed:author | pubmed-author:RicciPP | lld:pubmed |
| pubmed-article:1317344 | pubmed:author | pubmed-author:MiglioliMM | lld:pubmed |
| pubmed-article:1317344 | pubmed:author | pubmed-author:Mase'GG | lld:pubmed |
| pubmed-article:1317344 | pubmed:author | pubmed-author:BrillantiSS | lld:pubmed |
| pubmed-article:1317344 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1317344 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:1317344 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1317344 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1317344 | pubmed:pagination | 998-1001 | lld:pubmed |
| pubmed-article:1317344 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:meshHeading | pubmed-meshheading:1317344-... | lld:pubmed |
| pubmed-article:1317344 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1317344 | pubmed:articleTitle | Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C. | lld:pubmed |
| pubmed-article:1317344 | pubmed:affiliation | Department of Internal Medicine and Gastroenterology, University of Bologna, Italy. | lld:pubmed |
| pubmed-article:1317344 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1317344 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1317344 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1317344 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1317344 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1317344 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1317344 | lld:pubmed |
